Overview
Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder caused by mutations or deletions in the TCF4 gene located on chromosome 18q21.2. The condition was first described by Pitt and Hopkins in 1978 and is characterized by severe intellectual disability, distinctive facial features, and breathing abnormalities. Pitt-Hopkins syndrome primarily affects the nervous system, leading to absent or severely limited speech, motor delays, and moderate to severe intellectual disability. Many individuals never achieve independent walking, and most require lifelong support for daily activities. The characteristic facial features of PTHS include a wide mouth with a cupid's bow-shaped upper lip, widely spaced teeth, a broad nasal bridge with a beaked nasal tip, deep-set eyes, and prominent ears. A hallmark feature is episodic hyperventilation followed by apnea (breath-holding), which typically begins in early childhood and may worsen with excitement or anxiety. Individuals frequently exhibit a happy, sociable demeanor with frequent smiling and laughter. Seizures occur in approximately 30-50% of affected individuals and may begin at various ages. Gastrointestinal problems, including chronic constipation, are common. Some individuals may also have microcephaly, short stature, stereotypic hand movements, and abnormalities of the corpus callosum or hippocampus on brain imaging. There is currently no cure for Pitt-Hopkins syndrome, and treatment is symptomatic and supportive. Management typically involves a multidisciplinary approach including speech therapy, physical therapy, occupational therapy, and behavioral interventions. Antiepileptic medications are used when seizures are present. Breathing abnormalities may be managed with acetazolamide or other medications in some cases, though evidence remains limited. Ongoing research into potential targeted therapies, including gene therapy approaches, is underway but remains in early stages.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Infantile
Begins in infancy, roughly 1 month to 2 years old
FDA & Trial Timeline
2 eventsMahzi Therapeutics — PHASE1, PHASE2
Unravel Biosciences, Inc. — PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Pitt-Hopkins syndrome.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Pitt-Hopkins syndrome.
Community
No community posts yet. Be the first to share your experience with Pitt-Hopkins syndrome.
Start the conversation →Latest news about Pitt-Hopkins syndrome
Disease timeline:
New recruiting trial: Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
A new clinical trial is recruiting patients for Pitt-Hopkins syndrome
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Pitt-Hopkins syndrome
What is Pitt-Hopkins syndrome?
Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder caused by mutations or deletions in the TCF4 gene located on chromosome 18q21.2. The condition was first described by Pitt and Hopkins in 1978 and is characterized by severe intellectual disability, distinctive facial features, and breathing abnormalities. Pitt-Hopkins syndrome primarily affects the nervous system, leading to absent or severely limited speech, motor delays, and moderate to severe intellectual disability. Many individuals never achieve independent walking, and most require lifelong support for daily activities.
How is Pitt-Hopkins syndrome inherited?
Pitt-Hopkins syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Pitt-Hopkins syndrome typically begin?
Typical onset of Pitt-Hopkins syndrome is infantile. Age of onset can vary across affected individuals.
Are there clinical trials for Pitt-Hopkins syndrome?
Yes — 1 recruiting clinical trial is currently listed for Pitt-Hopkins syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Pitt-Hopkins syndrome?
1 specialists and care centers treating Pitt-Hopkins syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.